We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacological Effects of Neurapas® Balance and Pascoflair® 425 mg on Brain Activity in Healthy Volunteers (NCAG 5209)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01047605
First Posted: January 13, 2010
Last Update Posted: May 17, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Pascoe Pharmazeutische Praeparate GmbH
  Purpose
To evaluate the pharmacological effects of two herbal medicinal products (Neurapas balance and Pascoflair 425 mg) in comparison to placebo on brain activity.

Condition Intervention Phase
Healthy Drug: Neurapas balance Drug: Pascoflair 425 mg Drug: P-Tabletten weiß Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: Evaluation of the Pharmacological Effects of NEURAPAS® Balance and PASCOFLAIR® 425 mg by Quantitative Measurement of Brain Activity in 16 Healthy Volunteers. A Single-blinded, Randomised, Placebo-controlled, 3-armed Phase-I-study With Cross-over Design

Further study details as provided by Pascoe Pharmazeutische Praeparate GmbH:

Primary Outcome Measures:
  • Z1: qEEG (total): Median change of electrical activity (qEEG: of all electrode positions) compared to Baseline (PP1 vs PP2 vs Placebo) [ Time Frame: 5 times within 4 h ]

Secondary Outcome Measures:
  • Comparison PP1 vs PP2 vs Placebo: Z2: qEEG (all frequencies, Clusters): Median change of electrical activity (qEEG: of selective brain-regional clusters of electrode positions) compared to Baseline [ Time Frame: 5 times within 4 h ]
  • Comparison PP1 vs PP2 vs Placebo: Z3:qEEG (d2, beta1 (Cluster F7/T3)) [ Time Frame: 5 times wihtin 4 h ]
  • Comparison PP1 vs PP2 vs Placebo: Z4:qEEG (ME, theta (Cluster F7/T3/T6)) [ Time Frame: 5 times within 4 h ]
  • Comparison PP1 vs PP2 vs Placebo: Z5:qEEG (KLT, theta (Cluster F7/T3) + alpha (Cluster T4/T6)) [ Time Frame: 5 times within 4 h ]
  • Comparison PP1 vs PP2 vs Placebo: Z6: qEEG (Aa, all frequencies, Cluster C3/T3/P4) [ Time Frame: 5 times within 4 h ]
  • Comparison PP1 vs PP2 vs Placebo: Z7: Timely onset of effect and duration of effect [ Time Frame: 5 times within 4 h ]

Estimated Enrollment: 16
Study Start Date: January 2010
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PP1
Neurapas balance
Drug: Neurapas balance
6 tablets single dose
Experimental: PP2
Pascoflair 425 mg
Drug: Pascoflair 425 mg
3 tablets , single dose
Placebo Comparator: PL1
P-Tabletten weiß
Drug: P-Tabletten weiß
3 tablets, single dose

Detailed Description:
Evaluation of the pharmacological effects of Neurapas® balance and Pascoflair® 425 mg by quantitative measurement of brain activity in 16 healthy volunteers.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male and female volunteers
  • 30 - 70 years (extremes included)
  • Medical history without any study relevant pathological findings
  • Written and signed informed consent

Exclusion Criteria:

  • Clinically study relevant acute or chronic disorders, that can be detected by clinical investigation or medical history
  • Clinical, study-relevant pathological findings of clinical oar laboratory investigations
  • Clinically relevant pathological EEG findings (e.g. artefact-free parts in Screening-EEG <30% in one recording
  • Clinically relevant allergies
  • positive alcohol testing on Screening, Day A, B, or C, or anamnestic
  • positive drug screening test on Screening, Day A, B, or C, or anamnestic
  • Intake of study relevant medication 14 days prior to active Day A, or during active study duration, based on the volunteer´s information
  • Regular intake of drug with primary central nervous effects (e.g. psychoactive drugs or central acting antihypertensive drugs)
  • Known hypersensitivity / allergy against herbal extracts (i.e. dry extracts of Passionflower herb, St. John´s Wort herb, Valerian root) or lactose or an other excipient of the investigational medication
  • Lapp-lactase deficiency (anamnestic)
  • Hypersensitivity of the skin (anamnestic)
  • BMI (Body-Mass-Index) <18 or>30
  • Abuse of caffeine, teeine, or tobacco
  • Smoking in the investigational site on Day A, B, or C
  • Participation in an other clinical study within 60 days prior to Screening
  • Positive Pregnancy Test (on Screening, Day A, B, or C) or Lactation
  • Bad compliance
  • Revocation of informed consent
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01047605


Locations
Germany
Neurocode AG
Wetzlar, Germany, D-35578
Sponsors and Collaborators
Pascoe Pharmazeutische Praeparate GmbH
Investigators
Principal Investigator: Winfried Wedekind, MD, PhD Neurocoed AG, Sportparkstr. 9, D-35578 Wetzlar, Germany
Study Chair: Wilfried Dimpfel, Prof Neurocode AG, Sportparkstr. 9, D-35578 Wetzlar, Germany
Study Director: Anja Braschoss, MD Pascoe Pharmazeutische Praeparate GmbH
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Anja Braschoss, MD, PASCOE pharmazeutische Praeparate GmbH
ClinicalTrials.gov Identifier: NCT01047605     History of Changes
Other Study ID Numbers: 173 S 09 PSY
2009-015827-97 ( EudraCT Number )
First Submitted: January 12, 2010
First Posted: January 13, 2010
Last Update Posted: May 17, 2010
Last Verified: May 2010

Keywords provided by Pascoe Pharmazeutische Praeparate GmbH:
qEEG
herbal medicine
cognitive function
Neurapas balance
Pascoflair
hypericum
passionflower
valerian
Healthy volunteers
Influence on quantitative electro-encephalogram (qEEG).